Association between a low baseline level of gene expression of energy metabolism in the blood and the development of clinical remission in response to tofacitinib therapy in patients with rheumatoid arthritis
Background. Rheumatoid arthritis (RA) is an autoimmune disease of unknown etiology, characterized by erosive arthritis (synovitis) and systemic inflammation. Janus kinase (JAK) inhibitors (JAKi) are small molecules that block major signal pathways of many cytokines a growth factors, associated with...
Saved in:
Main Authors: | E. V. Chetina, A. M. Satybaldyev, G. A. Markova, E. Yu. Samarkina, M. V. Cherkasova |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2021-06-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/1143 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
NEW APPROACHES TO PHARMACOTHERAPY OF RHEUMATOID ARTHRITIS: TOFACITINIB
by: E. L. Nasonov
Published: (2014-06-01) -
Experience with tofacitinib in the treatment of resistant rheumatoid arthritis
by: A. R. Babaeva, et al.
Published: (2015-06-01) -
Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)
by: E. L. Nasonov, et al.
Published: (2020-02-01) -
The progress of rheumatology in the 21st century potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases
by: E. L. Nasonov, et al.
Published: (2020-11-01) -
The marked and rapid therapeutic effect of tofacitinib in combination with subcutaneous methotrexate in a rheumatoid arthritis patient with poor prognostic factors who is resistant to standard disease-modifying antirheumatic drugs and biologicals: A clinical case
by: N. V. Demidova, et al.
Published: (2016-03-01)